retatrutide ly3437943 parkinson's disease clinical trial (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Results Triple hormone receptor agonist retatrutide

As cardiovascular risk climbs after menopause, we know that when we lose our estrogen, our risk for cardiovascular events goes up, up, up

For now, GLP-1s remain legal in competition

See more Clenbuterol is an anabolic agent that is prohibited at all times (i.e., both in- and out-of-competition)

The Timing Hypothesis This distinction gave rise to what is now called the timing hypothesis: the idea that the risks and benefits of HRT are critically dependent on when therapy begins relative to the onset of menopause [12]

The base case, based on the company's prior pattern with tirzepatide, is that filing follows within roughly six months of TRIUMPH-1 topline